ABSTRACT OBJECTIVES The aim of this paper was to identify sex differences in survival of patients awaiting orthotopic heart transplantation (OHT).
W omen in the United States have a higher mortality rate than men while awaiting orthotopic heart transplantation (OHT) (1), which has not been fully evaluated. Based on publicly available Scientific Registry of Transplant Recipients (SRTR) data, the median OHT wait time for women during this same time period was shorter than for men (1) , suggesting it was not due to availability of donors. In 1 small European study (58 women, 260 men), more women (17%) than men (12%) died awaiting OHT during a 12-month follow-up. After adjusting for age, heart failure survival score, serum creatinine, inpatient status, cardiac index, low vocational level, smoking, and low emotional support at time of transplant listing, female sex was still associated with a higher risk of death/deterioration (hazard ratio [HR]: 2.3; 95% confidence interval [CI]: 1.04 to 5.12; p ¼ 0.04) (2) . What remains unknown is whether sex differences in waitlist mortality also exist in the United States after adjusting for baseline risk factors.
The current OHT allocation system in the United States is based primarily on severity of illness (3). However criteria for OHT listing and heart failure (HF) survival models (4-6) do not distinguish women from men despite known sex differences in cause (7) (8) (9) , cardiac remodeling (10) (11) (12) , response to therapy (13-16), and prognosis (17) (18) (19) . Therefore, advanced HF therapies such as OHT or mechanical circulatory support may be recommended with no evidence-based expectations if sex differences in prognostic risk factors are not recognized and utilized. The goal of this study was to further evaluate sex differences in mortality for HF patients awaiting OHT, using our current allocation system that stratifies patients into categories based on severity of illness: United Network for Organ Sharing (UNOS) status 1A for high-risk that could be implanted in petite patients (body surface area: <1.5 m 2 ), we also assessed the importance of the era before and after that date to look for any sex interaction.
METHODS SCIENTIFIC REGISTRY OF TRANSPLANT RECIPIENTS.
This study used data from SRTRs. The SRTR database includes data for all donors, waitlisted candidates, and transplantation recipients in the United States submitted by members of the Organ Procurement and Transplantation Network (OPTN) and has been described elsewhere (20 Hsich et al.
Mortality on the Heart Transplant Waiting List values than men. Right-heart catheterization showed slightly better hemodynamics for UNOS status 2 than 1A patients, with no sex differences except for lower cardiac output among women than among men in all subgroups. ABO blood types, previous cerebral vascular accident, and history of peripheral vascular disease were similar among all subgroups. Few patients were undergoing dialysis.
WAITLIST MORTALITY. There were 1,290 women and 4,286 men who died during a median follow-up of 3.7
years. Women had a statistically significant worse survival than men when initially listed for OHT as UNOS status 1A ( Fig. 1 ) but a better survival than men when listed as UNOS status 2 ( Fig. 2 ). There were no significant sex differences in survival for patients initially listed as UNOS status 1B.
Higher mortality in women than in men initially listed as UNOS status 1A was associated with lower likelihood for undergoing OHT (Fig 3A) . Lower mortality in women than in men initially listed as UNOS status 2 was associated with higher likelihood for OHT (Fig. 3C ). There were no significant sex differences in competing outcomes between transplantation and death among patients awaiting OHT as UNOS status 1B patients (Fig. 3B) . Both women and men in all UNOS subgroups had the highest mortality and transplantation rate within the first year after
listing. There was a plateau in the mortality and transplantation curves around the second and third years after listing, except for the mortality curve
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Mortality on the Heart Transplant Waiting List (2) 155 (2) 77 (2) 210 (2) Other 16 (1) 36 (1) 29 (1) 46 (1) 45 (1) 116 (1) BMI, kg/m 2 14-19 181 (12) 196 (4) 236 (11) 243 (4) 260 (8) 233 (2) 20-24 561 (37) 1,342 (29) 735 (33) (14) 986 (21) 441 (20) 1,542 (22) 725 (22) 2,763 (27) 35-40 92 (6) 274 (6) 153 (7) 498 (7) 249 (8) (14) 325 (14) 931 (14) 398 (12) (22) 141 (6) 440 (6) 32 (1) 118 (1) Continued on the next page Hsich et al. (22) 55 (2) 173 (3) 20 (1) 96 (1) Values are median (interquartile range) or n (%). *Frequency <10 patients.
BMI ¼ body mass index; CAD ¼ coronary artery disease; CMP ¼ cardiomyopathy; CO ¼ cardiac output; CVA ¼ cerebral vascular accident; ECMO ¼ extracorporeal membrane oxygenation; eGFR ¼ estimated glomerular filtration rate; IABP ¼ intra-aortic balloon pump; ICD ¼ implantable cardioverter-defibrillator; LVAD ¼ left ventricular assist device; MCS ¼ mechanical circulatory support; OHT ¼ orthotopic heart transplant; PAP ¼ pulmonary arterial pressure; PVD ¼ peripheral vascular disease; PVO2 ¼ peak oxygen consumption; RVAD ¼ right ventricular assist device; TAH ¼ total artificial heart.
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DISCUSSION
In a large, national transplantation registry, we found sex differences in mortality while patients awaited OHT. After we adjusted for possible confounding variables, female sex was associated with a higher risk of death among patients listed initially as UNOS status 1A, and male sex was associated with a higher risk of death among patients listed initially as UNOS status 2. No sex differences were noted among UNOS status 1B patients.
Our study adds to the growing concern that the current OHT allocation system needs to be refined (22) (23) (24) . Over the last decade, there has been no significant change in the number of OHTs in the United States annually despite a high waitlist mortality (25) . To minimize death on the waiting list, the current transplantation allocation system was based primarily on severity of illness. However, recent studies raise concern regarding racial disparity (26) , appropriateness of elective 30-day UNOS status 1A time for patients with an LVAD (24, 27, 28) , and transplantation of stable UNOS status 2 HF patients (29) . Our study adds to this literature suggesting that a sex-specific disparity exists in waitlist survival.
Few studies have evaluated sex differences in mortality while patients await OHT (2, 30) . One small European study noted women had a higher mortality rate than men awaiting OHT, which remained after Patients were stratified by UNOS status, and based on univariate logistic regression models, women initially listed as UNOS status 1A or 1B had a higher risk than men for death/delisting due to severity of illness and a lower chance than men for transplantation, whereas the opposite was true for UNOS status 2 patients. The authors concluded that women benefited from being listed as UNOS status 2 and that removing this status would result in a larger sex disparity (30).
Our study found similar sex differences in mortality while patients awaited OHT as UNOS status 1A and 2 patients, even after multivariate analysis accounting for >30 possible confounders.
The disparity in survival rates between women and men is of concern given the limited number of donor hearts available every year and the limited research in this field to further evaluate cause. For patients initially listed as UNOS status 1A, more women than men died on the waiting list. Based on the characteristics available that identified UNOS status 1A patients, we found women and men to have a similar profile at time of listing (22.2% Kaplan-Meier survival curves for women and men initially listed as UNOS status 1A upon listing for heart transplantation. Censored for heart transplantation. UNOS ¼ United Network for Organ Sharing. Kaplan-Meier survival curves for women and men initially listed as UNOS status 2 upon listing for heart transplantation. Censored for heart transplantation. UNOS ¼ United Network for Organ Sharing.
Mortality on the Heart Transplant Waiting List A U G U S T 2 0 1 4 : 3 4 7 -5 5 predicted vs. 21.8% actual females and 20.9% predicted vs. 21.2% actual males were UNOS status 1A at time of listing). Therefore, the higher mortality rate in women than in men was less likely due to sex differences in severity of illness at time of listing.
UNOS status 1A women were less likely than men to be bridged with VAD or TAH support at time of transplantation and more likely than men to be temporarily inactivated. The data remain limited, but these findings raise concern that women were not successfully bridged to transplantation while they remained at high status and were inactivated due to worsening condition. Objective evidence to support this is limited in the SRTR database as there was a high rate of missing important variables like hemodynamics, and data were only available at discrete time points (time of listing, time of transplantation, and change in status), preventing capture of any change in variable that affects prognosis but not UNOS status. We also did not have information as to why fewer women received mechanical circulatory support, which might have been due to fewer women than men being eligible for devices or fewer women than men who consented to devices. However, it is important to mention that the risk of survival for women did not change even after adjusting for >30 variables including mechanical circulatory support and era pre-and post-FDA approval of HeartMate II. As for UNOS status 2 patients, the differences in survival between women and men likely has to do with a lack of sex-specific OHT guidelines for peak oxygen consumption (31).
We and others have shown that women tend to live longer than men with the same peak oxygen consumption value (32, 33) . Therefore, perceived differences in survival of ambulatory patients may be due to premature listing of women as UNOS status 2 when peak oxygen consumption values are similar to those in men. Unfortunately, this hypothesis cannot be explored because data for peak oxygen consumption were missing from approximately 50% of patients in the SRTR database, even in the cohort listed as UNOS status 2. However, it is supported by the fact that women had better survival than men on the waiting list despite fewer women receiving VAD or TAH support at time of transplantation and fewer women than men at higher status at time of OHT.
Sex differences in survival while awaiting OHT is a concern, and despite not identifying the cause, a solution to reduce mortality must be found. We propose changing a "rule-based" heart transplant allocation system to a "survival model-based" allocation system to account for sex differences in survival. We also propose making the process dynamic so that as variables for an individual change, the level of risk is adjusted. The lung allocation system is the best example, whereby regression models are used to balance differences and assign a weight score that is used to rank patients. The lung transplant waitlist survival model includes variables like oxygen dependency at rest, mechanical ventilation, pulmonary artery pressures, 6-min walk distance, and would not be expected to alter the data significantly.
It is also important to mention that the database is not inclusive of all objective data. In our multivariate analysis some important variables were not utilized such as natriuretic peptides, panel of reactive antibody and cardiac index. The lack of these variables, which were not available, limits the analysis not only for our study but also for future studies that may help in changing the allocation system. However, for the purpose of this study, it is unlikely that the proportion of missing data elements was systematically and markedly different by candidate sex. Thus, the potential for this incomplete data to alter the qualitative findings of the study should be minimal but does prevent further understanding of sex differences in waitlist survival. Another important limitation is the fact that baseline data entered may not be standardized. For instance, peak VO 2 (ml/kg/min) is calculated using an individual's weight, but there is no requirement to use lean body mass despite sex differences in body composition. Furthermore, if lean body mass is used to calculate peak VO 2 , there is no requirement as to how to calculate it (i.e., estimated 
CONCLUSIONS
In a large, national registry, we found sex differences in survival among patients awaiting OHT even after rigorous multivariable risk adjustment. The cause remains unknown but should raise concern as the current UNOS transplant criteria does not account for this disparity. 
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